Novel therapies in CIDP

Journal of Neurology Neurosurgery & Psychiatry, Journal Year: 2024, Volume and Issue: unknown, P. jnnp - 334165

Published: Oct. 2, 2024

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous but clinically well-described disease within circumscribed parameters. It immunologically mediated through several poorly understood mechanisms. First-line therapies with steroids, intravenous immunoglobulin (IVIG) or plasma exchange are each effective in about two-thirds of patients. These treatments seldom associated complete resolution cure, and often pose considerable practical, financial medical implications. Our understanding many the key pathological processes autoimmune diseases expanding, novel targeted therapeutics being developed promise neurological disorders. This narrative review looks first at detailing pathogenic mechanisms CIDP, followed by an in-depth description potential current evidence their application clinical practice.

Language: Английский

Bortezomib Led to Remission of Immune Thrombocytopenic Purpura in a Patient with Smoldering Multiple Myeloma

Internal Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

A 79-year-old man with smoldering multiple myeloma (MM) developed sudden severe thrombocytopenia and active bleeding. Since anti-GPIIb/IIIa autoantibodies were detected on the platelet surface, due to an autoimmune etiology was diagnosed. Although neither steroids nor intravenous immunoglobulins provided improvement, bortezomib rapid normalization of counts disappearance anti-GPIIb/IIIb autoantibodies. MM is rarely associated immune thrombocytopenic purpura (ITP). underlying pathogenesis ITP remains elusive, anti-myeloma drugs might be beneficial.

Language: Английский